Core Insights - Galmed Pharmaceuticals announced significant top-line results from its AM-001 Study, a Phase 1 Bioavailability Study of Aramchol meglumine, indicating a notable improvement in bioavailability compared to Aramchol free acid tablets [1] Group 1: Bioavailability Results - The bioavailability of Aramchol meglumine 400mg granules is 5-fold greater than that of the Aramchol free acid 300mg tablets [1] - The bioavailability of Aramchol meglumine 200mg granules is 3-fold greater than that of the Aramchol free acid 300mg tablets [1] Group 2: Therapeutic Implications - The new pharmacokinetic profile allows for a once daily therapeutic regimen, which may enhance long-term adherence to the treatment [1] - The expected improvement in adherence is anticipated to significantly reduce the drug cost of goods [1]